Racecadotril 15mg + Saccharomyces boulardii 282.5mg + Zinc 7.5mg per sachet
GUTGEAR is a pharmacologically sophisticated triple-combination for paediatric acute diarrhoea management — combining an antisecretory agent, a proven probiotic, and an evidence-based micronutrient to address acute diarrhoea through three distinct mechanisms simultaneously.
Racecadotril 15mg (also known as acetorphan) is a prodrug that is hydrolysed in the intestinal mucosa to thiorphan — a potent and selective inhibitor of enkephalinase (neutral endopeptidase, NEP). Enkephalinase normally degrades endogenous enkephalins (endorphin-like neuropeptides) in the intestinal submucosa. By inhibiting enkephalinase, racecadotril increases local enkephalin concentrations, which then act on delta-opioid receptors on enterocytes to reduce cyclic AMP levels and decrease intestinal hypersecretion. This antisecretory mechanism is fundamentally different from loperamide — racecadotril reduces water and electrolyte secretion into the gut lumen without affecting intestinal motility or causing constipation. It works specifically at the secretory level, not the motor level — making it safe for use in infants where motility-modifying agents are contraindicated.
Saccharomyces boulardii 282.5mg is a non-pathogenic yeast probiotic with the most extensive evidence base of any probiotic for acute paediatric diarrhoea. Its mechanisms include: direct anti-pathogen activity (producing protease enzymes that degrade bacterial toxins), restoration of brush border enzyme activity (sucrase, maltase, isomaltase — reduced during diarrhoeal illness), stimulation of secretory IgA production, reduction of pro-inflammatory cytokine expression in the intestinal mucosa, and competitive inhibition of pathogen adhesion to enterocytes. Unlike bacterial probiotics, S. boulardii is inherently resistant to antibiotics — allowing co-administration during antibiotic therapy without being killed by concurrent antibiotic treatment.
Zinc 7.5mg replaces the zinc depleted during acute diarrhoeal illness and directly improves intestinal barrier function, enhances mucosal immunity, reduces intestinal hypersecretion through direct inhibitory effects on cAMP, and shortens diarrhoea duration — as validated in WHO's recommendation of zinc supplementation for all children with acute diarrhoea.
GUTGEAR is specifically designed for paediatric acute secretory diarrhoea — combining antisecretory, probiotic, and micronutrient mechanisms in the most clinically rational combination available.
Acute Watery Diarrhoea in Children (Primary): The primary and most evidence-supported indication. The triple combination addresses diarrhoea from multiple angles: racecadotril reduces hypersecretion (stopping the diarrhoea mechanistically), S. boulardii restores intestinal microbiome and brush border function (accelerating recovery), and zinc replaces depleted micronutrient and enhances immune-mediated recovery.
Rotavirus Diarrhoea: The most common cause of severe paediatric diarrhoea — S. boulardii has specific evidence for rotavirus diarrhoea reduction, and racecadotril's antisecretory mechanism addresses the rotavirus toxin-mediated hypersecretion directly.
Antibiotic-Associated Diarrhoea: S. boulardii's antibiotic resistance makes it the preferred probiotic during and after antibiotic courses — preventing Clostridium difficile overgrowth and restoring disturbed microbiome.
Traveller's Diarrhoea in Children: The combination covers both the acute phase (racecadotril antisecretory) and recovery phase (S. boulardii microbiome restoration) of traveller's diarrhoea.
Post-Gastroenteritis Microbiome Recovery: S. boulardii and zinc together accelerate restoration of normal gut flora after acute gastroenteritis resolution.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
Paediatric acute diarrhoea is one of the leading causes of childhood morbidity in India — and its management has been revolutionised by the availability of agents like racecadotril, which reduces the diarrhoeal fluid loss directly without the motility-suppressing risks of older antidiarrhoeal agents. Previous generations of antidiarrhoeal therapy (loperamide, atropine-containing combinations) are now contraindicated in children under 2 years due to paralytic ileus risks — leaving a genuine therapeutic gap that racecadotril fills safely.
S. boulardii's antibiotic resistance is uniquely important in the Indian context where acute diarrhoea in children is frequently treated with concurrent antibiotics (often inappropriately, but this is the clinical reality). Unlike Lactobacillus probiotics which are killed by concurrent antibiotics, S. boulardii survives antibiotic co-administration, providing probiotic benefit even when children are simultaneously receiving antimicrobial therapy.
GUTGEAR at ₹750 for 20 sachets positions the product at the premium paediatric diarrhoea management segment — reflecting the clinical value of the three-component combination and differentiating it from commodity ORS or simple zinc sachets.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.